Stanford L. Peng - 04 Jan 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Role
President & Head of Research and Development
Signature
James Paul Rickey, attorney-in-fact
Issuer symbol
N/A
Transactions as of
04 Jan 2024
Net transactions value
$0
Form type
4
Filing time
05 Jan 2024, 18:08:07 UTC
Previous filing
05 Jan 2023
Next filing
10 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Award $0 +48,000 +197% $0.000000 72,371 04 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALPN Stock Option (Right to buy) Award $0 +120,000 $0.000000 120,000 04 Jan 2024 Common Stock 120,000 $18.33 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received grant of restricted stock units ("RSUs") for no consideration. One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025 July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to the Reporting Person continuing to be a Service Provider through each such date.
F2 The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F3 One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.

Remarks:

President & Head of Research and Development